Helix BioPharma approves the selection of Director Robert Verhagen as CEO; plans to voluntarily delist from NYSE MKT (HBP) 1.40 : Co announces that its Board has approved the selection of Robert Verhagen as Chief Executive Officer. Verhagen is currently a Director for co. Co also announces that the Board has approved the voluntarily delisting of Helix's common shares from the NYSE MKT. The common shares will continue to trade on the Toronto Stock Exchange under the ticker symbol HBP and the co will continue to file the necessary reports with Canadian Securities.
Helix BioPharma provides update to shareholders; appoints William White as interim CEO on Thursday after the close (HBP) 1.75 : Co announces approved the initiation of Helix's planned Polish Phase I/II clinical trial of its lung cancer drug candidate L-DOS47 according to the approved protocol beginning with the monotherapy arm. The co currently plans to commence patient recruitment in this study before the end of its third fiscal quarter in April 2012, and will report on the expected schedule for this study when it is available. William White, Helix's Chairman of the Board, has been appointed as interim Chief Executive Officer to replace Donald Segal who has resigned as of the date of this announcement, as was previously anticipated. In this capacity, White will oversee the management, operations and financing strategies of the Company in the short term and immediately implement a search for a permanent CEO.
RELATED QUOTES Symbol Price Change HBP.TO 1.86 +0.16
AURORA, ON--(Marketwire -11/16/11)- Helix BioPharma Corp. (TSX: HBP.TO - News) (AMEX: HBP.TO - News) (Frankfurt: HBP.TO - News) ("HBP" or "the Company") announces that its Board of Directors (the "Board") appointed a special committee of independent directors (the "Special Committee") to advise the Board with respect to the Company's annual general meeting of shareholders to be held on January 30, 2012 (the "Meeting"). The members of the Special Committee are Jack M. Kay and W. Thomas Hodgson. The Special Committee is being advised by Norton Rose OR LLP.
The Special Committee will be dealing with matters recently raised by certain shareholders who participated in private placements by the Company in Europe. In this regard, a number of issues relating to the activities of third parties and their compliance with applicable laws have come to the attention of the Company's management and Board of Directors and have been referred to the Special Committee for further investigations.
Separately, the Company has retained Kingsdale Shareholder Services Inc. to assist with solicitation matters for the upcoming Meeting. A management information circular will be distributed to shareholders in advance of the Meeting.
HBP $1.96 Helix BioPharma: Clinical hold removed for co's Topical Interferon Alpha-2b Phase II/III efficacy trial IND application (HBP) 1.96 : Co announces that the "clinical hold" on its investigational new drug application for its Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial has been removed by the FDA. The co is still in need of additional funding as well as strategic partner support before commencing this trial. As such, it does not currently have an estimated timeline for commencement or completion of this trial. The co hopes, however, that this FDA approval will be helpful in generating the support it requires